Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US/EU | 2021

Login to access report north_east
Contact sales account_box

For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
  • What are the hidden opportunities that developers could leverage?
  • How do current therapies for non-nasopharyngeal SCCHN, such as Keytruda and Opdivo, perform on key clinical attributes for this patient population?
  • What are the greatest unmet needs and most attractive opportunities in the treatment of non-nasopharyngeal SCCHN?
  • What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles for non-nasopharyngeal SCCHN?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2021

Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly

Key drugs: Erbitux, Keytruda, Opdivo

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east